Fractyl Health, Inc. Common Stock (GUTS NASDAQ) stock market data APIs
$1.8045
0.02(1.1%)
as of July 18, 2025
Try our APIs with
free plan!
Fractyl Health, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Prev. Close
1.8045
Open
1.82
High
1.9311
Low
1.7735
52 wk Range
0.873-4.37
Market Cap
87 668 K
Shares Outstanding
48 977 K
Revenue
60 000
EPS
-0.475
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Fractyl Health, Inc. Common Stock data using free add-ons & libraries
Get Fractyl Health, Inc. Common Stock Fundamental Data
Fractyl Health, Inc. Common Stock Fundamental data includes:
- Net Revenue: 60 000
- EBITDA: -95 834 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: -0.41
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Fractyl Health, Inc. Common Stock News
New
Canaccord Genuity reiterates Buy rating on Fractyl Health stock
Investing.com - Canaccord Genuity has reiterated its Buy rating and $12.00 price target on Fractyl Health Inc (NASDAQ:GUTS), currently trading at $1.79, following the company’s presentation of upd...
Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
12 of 13 participants maintained or lost weight at 3 months, with 6 of 13 losing additional weight after stopping GLP-1 therapy and undergoing Revita procedure Median weight remained stable through 3...
Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models
New findings demonstrated that a single dose of Rejuva was well tolerated in healthy animals, with no evidence of toxicity Rejuva-treated healthy animals exposed to a high fat diet were protected fro...
Fractyl Health receives two new patents for duodenal resurfacing tech
BURLINGTON, Mass. - Fractyl Health, Inc. (NASDAQ:GUTS), a clinical-stage medical technology company with a market capitalization of $95.5 million, has been granted two new U.S. patents that strengthen...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
